Nature Communications (Jan 2020)
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
Abstract
Immunoglobulin E (IgE) plays a central role in allergic responses, yet therapeutic targeting of IgE with antibodies such as omalizumab is met with various limitations. Here the authors characterize the molecular properties and crystal structure of a new anti-IgE antibody, ligelizumab, for mechanistic insights related to its enhanced suppression activity.